Neurocrine Biosciences (NBIX)

Executive Summary

Neurocrine Biosciences is a commercial-stage biopharmaceutical company dedicated to developing life-changing treatments for patients with neurological, neuroendocrine, and neuropsychiatric disorders. Its flagship product, Ingrezza (valbenazine), is the standard of care for tardive dyskinesia and generates robust revenue. The company also markets Ongentys (opicapone) for Parkinson's disease and has partnered with AbbVie on Orlissa (elagolix) for endometriosis. Neurocrine's pipeline is anchored by emerging muscarinic receptor agonists, including NBI-1117568, a novel M4 orthosteric agonist in Phase 3 for schizophrenia. Additional early-stage programs target Alzheimer's disease psychosis, congenital adrenal hyperplasia, and other CNS conditions. With a strong balance sheet and a focused R&D strategy, Neurocrine is well-positioned to sustain growth through label expansions and pipeline advancements.

Upcoming Catalysts (preview)

• H2 2027Phase 3 top-line data for NBI-1117568 in schizophrenia40% success
• 2026FDA decision on sNDA for Ingrezza expanded indication (e.g., bipolar disorder or generalized anxiety)60% success
• 2026Phase 2 data readout for NBI-1065844 in major depressive disorder or anhedonia50% success